Form 8-K - Current report:
SEC Accession No. 0001159036-25-000049
Filing Date
2025-11-07
Accepted
2025-11-07 08:02:52
Documents
15
Period of Report
2025-11-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20251106.htm   iXBRL 8-K 33418
2 EX-99.1 ex991halo-pricingpressrele.htm EX-99.1 25218
6 GRAPHIC halo-20251106_g1.jpg GRAPHIC 15840
7 GRAPHIC image_1a.jpg GRAPHIC 5251
  Complete submission text file 0001159036-25-000049.txt   217590

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20251106.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20251106_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20251106_pre.xml EX-101.PRE 12522
17 EXTRACTED XBRL INSTANCE DOCUMENT halo-20251106_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 251460581
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)